Cullinan Oncology
6 known investors
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
Investors · 6
In the news
- Cullinan Oncology stock hits 52-week high at $17.97 By Investing.cominvesting.com · 2026
- William Blair reiterates Cullinan Oncology stock rating on trial data By Investing.cominvesting.com · 2026
- Stifel raises Cullinan Oncology stock price target on autoimmune progress By Investing.cominvesting.com · 2026
- Cullinan Oncology Closes $98.5M Series B Financing Round - FinSMEsfinsmes.com · 2020
- Buy Cullinan Oncology Stock – CGEM Stock Quote Today & Investment Insights - Public.compublic.com
- Cullinan Oncology - Company Profile, Funding & News | Goldengolden.com